October 16, 2017
Ablynx names leader for its newly established USA subsidiary
Ablynx has expanded in the USA, with a subsidiary company, Ablynx Inc., as it has appointed Daniel Schneider as the General…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
October 13, 2017
CPhI Worldwide report highlights unpredictability in CDMO growth over next 5-years
CPhI Worldwide – held in Frankfurt, October 24-26 and organised by UBM – announces the findings of part i of the 5th edition of the CPhI Annual…
October 12, 2017
Anavex shows data from certain Alzheimer’s disease drug trial
Anavex Life Sciences has reported pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study in…
October 11, 2017
Envigo appoints new business consultatnt
Enviogo has appointed Dr. Naheed Rehman as new business lead consultant, chemicals – adding further specialist expertise to its team…
October 11, 2017
Piramal Pharma Solutions injects $55 million to expands its North America & Asia capacities
Contract Development and Manufacturing Organization (CDMO) Piramal Pharma Solutions (PPS), has invested $55 million across its sites in North America…
October 11, 2017
U.S. FDA fast tracks Astellas’s development of gilteritinib in certain myeloid leukemia
Astellas Pharma will have an expedited review process for gilteritinib, as the U.S. Food and Drug Administration (FDA) granted fast track…
October 10, 2017
Diplomat to sell Eli Lilly’s new cancer drug
Diplomat Pharmacy will dispense newly approved Eli Lilly’s Verzenio(abemaciclib), a twice-daily oral therapy for advanced breast cancer. Verzenio is indicated…
October 10, 2017
Lilly’s Verzenio failed to treat advanced non-small lung cancer
Eli Lilly’s Phase 3 JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced…
October 10, 2017
Pertinax Pharma launches CHX delivery control technology
Pertinax Pharma on Tuesday revealed launching of its Pertinax technology, which provides controlled and sustained delivery of chlorhexidine (CHX). The…
October 10, 2017
EDO takes another step for Tinostamustine, as first-in-human solid tumor study begins
Mundipharma EDO GmbH (EDO) has begun a US Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid…